Tenascin-C在乳腺导管原位癌的表达及其意义  

Expression of Tenascin-C in ductal carcinoma in situ of the breast and its clinical significance

作　　者：张奇兵[1] 管旌旌[1] 杨明[1] 大内宪明[2] 

机构地区：[1]吉林大学第一医院乳腺外科,吉林长春130021 [2]日本东北大学肿瘤外科,日本仙台9808574

出　　处：《吉林医学》2009年第5期396-397,共2页Jilin Medical Journal

基　　金：日本笹川奖学金资助课题

摘　　要：目的:探讨Tenascin-C(Tn-C)在乳腺导管原位癌中的表达及其意义。方法:应用免疫组化S-P方法检测52例乳腺导管原位癌Tn-C的表达,及其与ER、PR和HER-2等表达的相关性。结果:Tn-C表达阳性率为60%,其中Van-Nuys1组的阳性率为38%,Van-Nuys2组的阳性率为70%,Van-Nuys3组的阳性率为88%,组间阳性表达差异有统计学意义(P<0.01)。Tenascin-C的阳性表达和ER、PR阴性表达及HER-2阳性表达呈正相关(P<0.05)。结论:Tn-C可以作为判断乳腺导管原位癌恶性程度、预后的一个指标。Objective To investigate the expression of Tenasein - C （Tn - C） in ductal carcinoma in situ of the breast and its clinical significance. Method The expression of Tn - C, ER, PR and HER - 2 were examined in 52 patients with ductal carcinoma in situ of the breast by S - P immunohistochemical technique. Results The positive rate of Tn - C was 60%, and its positive expression in Van - Nuys group 1,2 and 3 was 38% ,70% and 88% ,respectively. There was significant difference among the three groups （ P 〈0.01 ）. Tenascin - C positive expression was strongly related to ER, PR negative expression and HER - 2 positive expression （P 〈 0.05）. Conclusion Tenascin - C may be a tumor marker for clinics and a parameter for prognosis of ductal carcinoma in situ of the breast.

关 键 词：乳腺癌 Tenascin—C 免疫组织化学 乳腺导管原位癌 

分 类 号：R737.9[医药卫生—肿瘤]